Market closed

Royalty Pharma/$RPRX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Ticker

$RPRX
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
New York, United States

Employees

-
Website
www.royaltypharma.com

Royalty Pharma Metrics

BasicAdvanced
$13B
11.76
$2.55
0.47
$0.84
2.93%

$13B

0.47

$31.66

$24.05

3.4M

$0.84

1.536

1.532

64.439

74.157

32.50%

7.46%

5.69%

17.28%

11.759

5.941

1.95

1.95

-63.372

2.80%

2.93%

-2.51%

518.56%

-0.29%

9.87%

7.94%

What the Analysts think about Royalty Pharma

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.

Royalty Pharma Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Royalty Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Royalty Pharma News

AllArticlesVideos
Royalty Pharma: Key Strategic Updates To Be Priced In

Royalty Pharma: Key Strategic Updates To Be Priced In

Seeking Alpha·3 hours ago
Royalty Pharma simplifies corporate structure with $1.1 bln deal

Royalty Pharma simplifies corporate structure with $1.1 bln deal

Reuters·5 days ago
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RPRX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Feb21
Royalty Pharma
Dividend·Ex-dividend
Mar10
Royalty Pharma
Dividend·Payment
$0.22
Per share

FAQs

What’s the current market cap for Royalty Pharma stock?

Royalty Pharma (RPRX) has a market cap of $13B as of January 15, 2025.

What is the P/E ratio for Royalty Pharma stock?

The price to earnings (P/E) ratio for Royalty Pharma (RPRX) stock is 11.76 as of January 15, 2025.

Does Royalty Pharma stock pay dividends?

Yes, the Royalty Pharma (RPRX) stock pays dividends to shareholders. As of January 15, 2025, the dividend rate is $0.84 and the yield is 2.93%. Royalty Pharma has a payout ratio of 32.5% on a trailing twelve-month basis.

When is the next Royalty Pharma dividend payment date?

The next Royalty Pharma (RPRX) dividend payment is scheduled for March 10, 2025.

What is the beta indicator for Royalty Pharma?

Royalty Pharma (RPRX) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.